当前位置: X-MOL 学术World J. Clin. Cases › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Complete withdrawal of glucocorticoids after dupilumab therapy in allergic bronchopulmonary aspergillosis: A case report.
World Journal of Clinical Cases ( IF 1.0 ) Pub Date : 2021-8-28 , DOI: 10.12998/wjcc.v9.i23.6922
Tadashi Nishimura 1 , Tomohito Okano 2 , Masahiro Naito 1 , Chikashi Tsuji 1 , Soichi Iwanaka 1 , Yasumasa Sakakura 1 , Taro Yasuma 3 , Hajime Fujimoto 2 , Corina N D'Alessandro-Gabazza 3 , Yasuhiro Oomoto 1 , Tetsu Kobayashi 4 , Esteban C Gabazza 3 , Hidenori Ibata 1
Affiliation  

Allergic bronchopulmonary aspergillosis (ABPA) is an allergic reaction to Aspergillus species that aggravates bronchial asthma. Previous studies demonstrated the glucocorticoid-sparing effect of dupilumab in patients with ABPA. There is no report of complete withdrawal of glucocorticoids after dupilumab.

中文翻译:

Dupilumab 治疗过敏性支气管肺曲霉病后完全停用糖皮质激素:病例报告。

过敏性支气管肺曲霉病 (ABPA) 是一种对曲霉菌属的过敏反应,可加重支气管哮喘。先前的研究证明了 dupilumab 对 ABPA 患者的糖皮质激素节约作用。没有关于在 dupilumab 后完全停用糖皮质激素的报告。
更新日期:2021-08-28
down
wechat
bug